Apixaban Study Halted – But It May Not Cause Much Damage To The Program

The Phase III APPRAISE-2 trial of Bristol-Myers Squibb/Pfizer’s apixaban in acute coronary syndrome has been terminated due to increased bleeding, on the recommendation of a data safety monitoring committee.